NCT04456036

Brief Summary

The purpose of the study is to apply a prospective observational design to describe the emerging functional impairments of subjects affected by COVID-19 in the acute phase and monitor their course and impact on activities and participation up to 12 months of onset. The ultimate goal is to provide a reliable framework to plan rehabilitation delivery to COVID-19 survivors in each phase and foresee health needs in the medium and long term. The secondary objective of the study is to find predictors of functional recovery, among pre-existing and emerging individual and contextual factors, with a special focus on the latency of rehabilitation start after hospital admission.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 30, 2020

Completed
1 day until next milestone

Study Start

First participant enrolled

July 1, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 2, 2020

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2021

Completed
Last Updated

April 27, 2021

Status Verified

April 1, 2021

Enrollment Period

6 months

First QC Date

June 30, 2020

Last Update Submit

April 26, 2021

Conditions

Keywords

COVID-19RehabilitationRecovery of FunctionActivities of Daily LivingPrognosisQuality of LifeContinuity of Patient Care

Outcome Measures

Primary Outcomes (3)

  • Change from pre-COVID-19 condition in ADL independence on the mod. Rankin scale score at the enrolment (T0) assessment, at 3, 6 and 12 months

    mod. Rankin scale is a rapid and validated measure of global independence in ADL with a score ranging from 0 (no disability) to 5 (bedridden). Change= pre-COVID mod. Rankin scale score (retrospective data) - mod. Rankin scale score prospectively collected at the enrolment (T0) and at 3, 6 and 12 months

    Pre-COVID status, at enrolment and at 3, 6 12-month follow-up

  • Change from pre-COVID-19 condition in walking performance on the Walking Handicap scale (WHS) at 3, 6 and 12 months

    The Walking Handicap scale is a quick and validated measure of walking performance, with a score ranging from 1 (Physiological walker: Walks for exercise only either at home or in parallel bars during physical therapy) to 6 (Community walker: Independent in all home and community activities. Can accept crowds and uneven terrain. Demonstrates complete independence in shopping centers). Change= pre-COVID WHS (retrospective data) - WHS score prospectively collected at 3, 6 and 12 months

    Pre-COVID status , and 3, 6 12-month follow-up

  • Patient-reported health-related well-being perception on the 36-Item Short Form Survey - SF-36 at 3, 6 12 months follow-up

    SF-36 is a widespread validated scale assessing patient-reported changes in health-related well-being perception over the last 4 weeks

    3, 6 and 12-month follow-up

Secondary Outcomes (7)

  • Change in global ADL disability on modified Barthel Index (mBI), from the enrolment (T0), at 3, 6 12 months follow-up

    the enrolment (T0) assesssment and 3, 6 and 12-month follow-up

  • Change in walking capacity on Functional Ambulation Category (FAC), from the enrolment (T0) assessment, at 3, 6 12 months follow-up

    Pre-COVID status, the enrollment (T0) assessment and 3, 6 12-month follow-up

  • Change in cognitive abilities on the Montreal Cognitive Assessment (MoCA) from the enrollment (T0) assessment, at 3, 6 12 months follow-up

    the enrollment (T0) assessment and 3, 6 and 12-month assessment follow-up

  • Change in patient-reported pain on Numerical Rating Scale from the enrollment (T0) assessment, at 3, 6 12 months follow-up

    the enrollment (T0) and 3, 6 and 12-month assessment follow-up

  • Change in swallow abilities on Dysphagia Outcome Severity Scale (DOSS) from the first functional assessment in acute care, at 3, 6 12 months follow-up

    the enrollment (T0) assessment and 3, 6 and 12-month assessment follow-up

  • +2 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adults, male and female, admitted to the University Hospital "Ospedali Riuniti of Ancona" (UH-ORA) from March 1st, 2020 for the management of acute COVID-19 infection, able to provide written or oral informed consent. The only exclusion criterion will be the lack of information concerning clinical data regarding the management in the acute ward.

You may qualify if:

  • age \>= 18 years,
  • any gender,
  • COVID-19 diagnosis: positive oro-pharyngeal swab for SARS-COV-2
  • admitted to the University Hospital "Ospedali Riuniti of Ancona" (UH-ORA) from March 1st, 2020 for the management of acute COVID-19,
  • able to provide written or oral informed consent.

You may not qualify if:

  • the lack of information concerning clinical data regarding the management in the acute ward.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Neurorehabilitation Clinic, University Hospital Ospedali Riuniti di Ancona

Ancona, 60122, Italy

RECRUITING

Related Publications (13)

  • Ceravolo MG, de Sire A, Andrenelli E, Negrini F, Negrini S. Systematic rapid "living" review on rehabilitation needs due to COVID-19: update to March 31st, 2020. Eur J Phys Rehabil Med. 2020 Jun;56(3):347-353. doi: 10.23736/S1973-9087.20.06329-7. Epub 2020 Apr 22.

    PMID: 32316718BACKGROUND
  • Andrenelli E, Negrini F, de Sire A, Arienti C, Patrini M, Negrini S, Ceravolo MG; International Multiprofessional Steering Committee of Cochrane Rehabilitation REH-COVER action. Systematic rapid living review on rehabilitation needs due to COVID-19: update to May 31st, 2020. Eur J Phys Rehabil Med. 2020 Aug;56(4):508-514. doi: 10.23736/S1973-9087.20.06435-7. Epub 2020 Jun 16.

    PMID: 32539312BACKGROUND
  • de Sire A, Andrenelli E, Negrini F, Negrini S, Ceravolo MG. Systematic rapid living review on rehabilitation needs due to COVID-19: update as of April 30th, 2020. Eur J Phys Rehabil Med. 2020 Jun;56(3):354-360. doi: 10.23736/S1973-9087.20.06378-9. Epub 2020 May 15.

    PMID: 32408729BACKGROUND
  • Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci. 2020 Jul;77:8-12. doi: 10.1016/j.jocn.2020.05.017. Epub 2020 May 6.

    PMID: 32409215BACKGROUND
  • Yang LL, Yang T. Pulmonary rehabilitation for patients with coronavirus disease 2019 (COVID-19). Chronic Dis Transl Med. 2020 May 14;6(2):79-86. doi: 10.1016/j.cdtm.2020.05.002. eCollection 2020 Jun.

    PMID: 32411496BACKGROUND
  • Brugliera L, Spina A, Castellazzi P, Cimino P, Arcuri P, Negro A, Houdayer E, Alemanno F, Giordani A, Mortini P, Iannaccone S. Nutritional management of COVID-19 patients in a rehabilitation unit. Eur J Clin Nutr. 2020 Jun;74(6):860-863. doi: 10.1038/s41430-020-0664-x. Epub 2020 May 20. No abstract available.

    PMID: 32433599BACKGROUND
  • Negrini S, Grabljevec K, Boldrini P, Kiekens C, Moslavac S, Zampolini M, Christodoulou N. Up to 2.2 million people experiencing disability suffer collateral damage each day of COVID-19 lockdown in Europe. Eur J Phys Rehabil Med. 2020 Jun;56(3):361-365. doi: 10.23736/S1973-9087.20.06361-3. Epub 2020 May 8.

    PMID: 32383576BACKGROUND
  • Bartolo M, Intiso D, Lentino C, Sandrini G, Paolucci S, Zampolini M; Board of the Italian Society of Neurological Rehabilitation (SIRN). Urgent Measures for the Containment of the Coronavirus (Covid-19) Epidemic in the Neurorehabilitation/Rehabilitation Departments in the Phase of Maximum Expansion of the Epidemic. Front Neurol. 2020 Apr 30;11:423. doi: 10.3389/fneur.2020.00423. eCollection 2020.

    PMID: 32425880BACKGROUND
  • Lew HL, Oh-Park M, Cifu DX. The War on COVID-19 Pandemic: Role of Rehabilitation Professionals and Hospitals. Am J Phys Med Rehabil. 2020 Jul;99(7):571-572. doi: 10.1097/PHM.0000000000001460.

    PMID: 32371624BACKGROUND
  • Li H, Xue Q, Xu X. Involvement of the Nervous System in SARS-CoV-2 Infection. Neurotox Res. 2020 Jun;38(1):1-7. doi: 10.1007/s12640-020-00219-8. Epub 2020 May 13.

    PMID: 32399719BACKGROUND
  • Valenzuela PL, Joyner M, Lucia A. Early mobilization in hospitalized patients with COVID-19. Ann Phys Rehabil Med. 2020 Jul;63(4):384-385. doi: 10.1016/j.rehab.2020.04.005. Epub 2020 May 18. No abstract available.

    PMID: 32418848BACKGROUND
  • Stein J, Visco CJ, Barbuto S. Rehabilitation Medicine Response to the COVID-19 Pandemic. Am J Phys Med Rehabil. 2020 Jul;99(7):573-579. doi: 10.1097/PHM.0000000000001470.

    PMID: 32433243BACKGROUND
  • Wang X, Xu H, Jiang H, Wang L, Lu C, Wei X, Liu J, Xu S. Clinical features and outcomes of discharged coronavirus disease 2019 patients: a prospective cohort study. QJM. 2020 Sep 1;113(9):657-665. doi: 10.1093/qjmed/hcaa178.

    PMID: 32442308BACKGROUND

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Maria Gabriella Ceravolo, MD PhD

    Dep. of Experimental and Clinical Medicine - University Politecnica delle Marche

    STUDY DIRECTOR

Central Study Contacts

Marianna Capecci, MD PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
12 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof

Study Record Dates

First Submitted

June 30, 2020

First Posted

July 2, 2020

Study Start

July 1, 2020

Primary Completion

December 31, 2020

Study Completion

June 30, 2021

Last Updated

April 27, 2021

Record last verified: 2021-04

Data Sharing

IPD Sharing
Will not share

The research results will be made available through indexed Journals as scientific publication.

Locations